Treating metastatic cancer and model systems for metastatic disease
AssigneeMemorial Sloan Kettering Cancer Center
InventorsKaruna Ganesh, Manuel Valiente, Joan Massague
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for inhibiting metastatic spread of cancer and/or inhibiting progression of pre-existing metastatic disease in a subject using L1CAM inhibition.
Claims22
A method of reducing the risk, in a subject who has received treatment for a primary cancer, of metastatic spread of the primary cancer, comprising administering to the subject a therapeutic amount of a L1CAM inhibitor.
A method of inhibiting metastatic spread of a primary cancer in a subject who has received treatment for the primary cancer, comprising administering to the subject a therapeutic amount of a L1CAM inhibitor.
A method of inhibiting progression of metastatic disease in a subject who has received treatment for the primary cancer, comprising administering to the subject a therapeutic amount of a L1CAM inhibitor.
A method of reversing chemoresistance of a cancer cell to a chemotherapy agent, comprising administering, to the cancer cell, an effective amount of L1CAM inhibitor.
An assay for identifying an agent that inhibits metastasis, comprising an organoid culture comprising cancer cells that express L1CAM.
A method of identifying an agent that inhibits metastasis, comprising:
- (i) providing an organoid culture comprising cancer cells that express L1CAM;
- (ii) contacting the organoid culture with a test agent;
- and
- (iii) determining whether the level of L1CAM expression decreases in the test agent-contacted culture relative to a control organoid culture that has not been contacted with the test agent;
- wherein a decrease in the level of L1CAM expression in response to contacting with the test agent indicates that the test agent inhibits metastasis.
A kit for identifying an agent that inhibits metastasis, comprising (i) cancer cells that express L1CAM and (ii) means for determining the L1CAM expression level.
A method of inhibiting progression of metastatic disease in a subject comprising administering to the subject a therapeutic amount of an agent that reduces L1CAM expression in cancer cells, for example via CRISPR/Cas9 mediated gene editing.
Dependencies are inferred from the claim text.